Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,079
  • Shares Outstanding, K 90,079
  • Annual Sales, $ 0 K
  • Annual Income, $ -93,610 K
  • EBIT $ -96 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.89
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.27

Options Overview Details

View History
  • Implied Volatility 236.17% ( -40.26%)
  • Historical Volatility 74.69%
  • IV Percentile 57%
  • IV Rank 26.62%
  • IV High 789.78% on 03/14/24
  • IV Low 35.34% on 08/22/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 10
  • Volume Avg (30-Day) 132
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 20,384
  • Open Int (30-Day) 20,123

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.26
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 unch
on 12/20/24
1.4200 -29.58%
on 12/02/24
-0.0700 (-6.54%)
since 11/20/24
3-Month
1.0000 unch
on 12/20/24
1.8883 -47.04%
on 09/23/24
-0.8300 (-45.36%)
since 09/20/24
52-Week
0.9700 +3.09%
on 06/26/24
2.1100 -52.61%
on 09/19/24
-0.2600 (-20.63%)
since 12/20/23

Most Recent Stories

More News
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.9600 (-1.75%)
ULY : 0.5030 (-4.14%)
IMUX : 1.0000 (-3.85%)
NMTC : 0.7582 (+0.03%)
SNGX : 2.95 (-4.22%)
TMG.VN : 0.190 (unch)
BLGO : 0.1950 (+8.64%)
FET : 14.21 (-1.80%)
ACFN : 18.0000 (-0.55%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0800 (-15.79%)
SOTK : 4.23 (-4.73%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 1.0000 (-3.85%)
Immunic: Q2 Earnings Snapshot

Immunic: Q2 Earnings Snapshot

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
ZS : 187.38 (+2.28%)
NOC : 469.54 (+0.52%)
LMT : 489.02 (+1.95%)
DAL : 60.93 (+0.91%)
AAL : 16.88 (+1.44%)
DDOG : 149.46 (+1.72%)
PEP : 152.79 (+0.87%)
ELIS.FP : 18.640 (+0.76%)
IMUX : 1.0000 (-3.85%)
AKRO : 29.34 (+3.31%)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as...

IMUX : 1.0000 (-3.85%)
Immunic to Participate in Scientific Conferences in October

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic to Participate in Industry and Investor Conferences in September

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)

Business Summary

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis....

See More

Key Turning Points

3rd Resistance Point 1.1667
2nd Resistance Point 1.1333
1st Resistance Point 1.0667
Last Price 1.0000
1st Support Level 0.9667
2nd Support Level 0.9333
3rd Support Level 0.8667

See More

52-Week High 2.1100
Fibonacci 61.8% 1.6745
Fibonacci 50% 1.5400
Fibonacci 38.2% 1.4055
Last Price 1.0000
52-Week Low 0.9700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar